Literature DB >> 25963509

Therapy. Statins and liver disease: from concern to 'wonder' drugs?

Jaume Bosch1, Xavier Forns1.   

Abstract

The benefits of statins go beyond decreasing cholesterol levels; in liver disease, statins reduce the risk of progressive liver fibrosis and provide protection during infections and ischaemia–reperfusion injury. New evidence shows that statins improve response to interferon-based anti-HCV therapy, decrease progression to cirrhosis and likelihood of developing hepatocellular carcinoma.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25963509     DOI： 10.1038/nrgastro.2015.78

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  9 in total

1.  Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.

Authors:  Adeel A Butt; Peng Yan; Hector Bonilla; Abdul-Badi Abou-Samra; Obaid S Shaikh; Tracey G Simon; Raymond T Chung; Shari S Rogal
Journal:  Hepatology       Date:  2015-05-23       Impact factor: 17.425

2.  Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.

Authors:  Chia-Hsuin Chang; Yi-Cheng Chang; Yen-Chieh Lee; Ying-Chun Liu; Lee-Ming Chuang; Jou-Wei Lin
Journal:  J Gastroenterol Hepatol       Date:  2015-01       Impact factor: 4.029

3.  KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.

Authors:  Giusi Marrone; Raquel Maeso-Díaz; Guillermo García-Cardena; Juan G Abraldes; Juan Carlos García-Pagán; Jaime Bosch; Jordi Gracia-Sancho
Journal:  Gut       Date:  2014-12-10       Impact factor: 23.059

4.  Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.

Authors:  Juan G Abraldes; Agustin Albillos; Rafael Bañares; Juan Turnes; Rosario González; Juan Carlos García-Pagán; Jaime Bosch
Journal:  Gastroenterology       Date:  2009-01-24       Impact factor: 22.682

Review 5.  Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.

Authors:  Qianqian Zhu; Na Li; Qunying Han; Pingping Zhang; Cuiling Yang; Xiaoyan Zeng; Yanping Chen; Yi Lv; Xi Liu; Zhengwen Liu
Journal:  Antiviral Res       Date:  2013-04-16       Impact factor: 5.970

6.  Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  James H Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R Medoff; Rene Belder
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

Review 7.  HCV and host lipids: an intimate connection.

Authors:  Esperance A K Schaefer; Raymond T Chung
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

8.  Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction.

Authors:  Vincenzo La Mura; Marcos Pasarín; Cintia Z Meireles; Rosa Miquel; Aina Rodríguez-Vilarrupla; Diana Hide; Jorge Gracia-Sancho; Juan Carlos García-Pagán; Jaime Bosch; Juan G Abraldes
Journal:  Hepatology       Date:  2013-01-25       Impact factor: 17.425

Review 9.  Hepatitis C virus life cycle and lipid metabolism.

Authors:  Costin-Ioan Popescu; Laura Riva; Ovidiu Vlaicu; Rayan Farhat; Yves Rouillé; Jean Dubuisson
Journal:  Biology (Basel)       Date:  2014-12-15
  9 in total
  7 in total

Review 1.  Nutrition and Hepatocellular Cancer.

Authors:  Kerstin Schütte; Christian Schulz; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2015-11-18

Review 2.  The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.

Authors:  Carlos Moctezuma-Velázquez; Juan G Abraldes; Aldo J Montano-Loza
Journal:  Curr Treat Options Gastroenterol       Date:  2018-06

Review 3.  Sinusoidal communication in liver fibrosis and regeneration.

Authors:  Giusi Marrone; Vijay H Shah; Jordi Gracia-Sancho
Journal:  J Hepatol       Date:  2016-05-02       Impact factor: 25.083

Review 4.  Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem.

Authors:  Guadalupe Garcia-Tsao; Jaime Bosch
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-17       Impact factor: 11.382

5.  A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.

Authors:  Sarai Rodríguez; Imma Raurell; Manuel Torres-Arauz; Teresa García-Lezana; Joan Genescà; María Martell
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

6.  Anti-CD321 antibody immunotherapy protects liver against ischemia and reperfusion-induced injury.

Authors:  Enzhi Yin; Takeshi Fukuhara; Kazuyoshi Takeda; Yuko Kojima; Kyoko Fukuhara; Kenichi Ikejima; Hisashi Bashuda; Jiro Kitaura; Hideo Yagita; Ko Okumura; Koichiro Uchida
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

7.  Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants.

Authors:  Amir Vahedian-Azimi; Sajad Shojaie; Maciej Banach; Farshad Heidari; Arrigo F G Cicero; Masoum Khoshfetrat; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.